Clinical Relevance of Pharmacogenetics

  • H. K. Kroemer
  • G. Mikus
  • M. Eichelbaum
Part of the Handbook of Experimental Pharmacology book series (HEP, volume 110)


One of the central problems in pharmacotherapy is the interindividual variability in response to drugs. While in vitro experiments show a close relationship between dose and resulting effects, large differences are observed once the same dose is administered to a population of patients.


Acetylator Phenotype Slow Acetylator Phenotype Debrisoquine Hydroxylation Polymorphic Oxidation Dibucaine Number 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Alvan G, von Bahr C, Seideman P, Sjöqvist F (1982) High plasma concentrations of β-receptor blocking drugs and deficient debrisoquine hydroxylation. Lancet 1: 333PubMedGoogle Scholar
  2. Alvan G, Grind M, Graffner C, Sjöqvist F (1984) Relationship of N-demethylation of amiflamine and its metabolite to debrisoquine hydroxylation polymorphism. Clin Pharmacol Ther 36: 515–519PubMedGoogle Scholar
  3. Anders HH, Weber WW (1986) N-acetylation pharmacogenetics: Michealis-Menten constants for aryamine drugs as predictors of their N-acetylation rates in vivo. Drug Metab Dispos 14: 382–385Google Scholar
  4. Andersson T, Regardh CG, Dahl-Puustinen ML, Bertilsson L (1990) Slow omeprazole metabolizers are also poor S-mephenytoin hydroxylators. Ther Drug Monit 12: 415–416PubMedGoogle Scholar
  5. Arns PA, Wilkinson GR, Branch RA (1988) The stereoselective disposition of mephenytoin provides a probe of hepatic function and development of portasystemic shunts in liver disease. Hepatology 8: 1277Google Scholar
  6. Ayesh R, Smith RL (1992) Genetic polymorphism of trimethylamine N-oxidation. In: Kalow W (ed) Pharmacogenetics of drug metabolism. Pergamon, New York, pp 315–333Google Scholar
  7. Balant-Gorgia AE, Balant LP, Genet C, Dayer P, Aeschlimann JM, Garrone G (1986) Importance of oxidative polymorphism and levomepromazine treatment on the steady-state blood concentrations of clomipramine and its major metabolites. Eur J Clin Pharmacol 31: 449–455PubMedGoogle Scholar
  8. Beckmann J, Hertrampf R, Gundert-Remy U, Mikus G, Gross AS, Eichelbaum M (1988) Is there a genetic factor in flecainide toxicity? Br Med J 297: 1326Google Scholar
  9. Bertilsson L, Mellström B, Sjöqvist F, Martensson B, Asberg M (1981) Slow hydroxylation of nortriptyline and concomitant poor debrisoquine hydroxylation: clinical implications. Lancet 1: 560–561PubMedGoogle Scholar
  10. Bertilsson L, Henthorn TK, Sanze E, Tybring G, Säwe J, Villen T (1989) Importance of genetic factors in the regulation of diazepam metabolism: relationship to S-mephenytoin, but not debrisoquine hydroxylation phenotype. Clin Pharmacol Ther 45: 348–355PubMedGoogle Scholar
  11. Blum M, Grant DM, McBride W, Heim M, Meyer UA (1990) Human arylamine N-acetyltransferase genes: isolation, chromosomal localisation and functional expression. DNA Cell Biol 9: 193–203PubMedGoogle Scholar
  12. Blum M, Demierre A, Grant DM, Heim M, Meyer UA (1991) Molecular mechanism of slow acetylation of drugs and carcinogens in humans. Proc Natl Acad Sci USA 88: 5237–5241PubMedGoogle Scholar
  13. Bönike R, Reif W (1953) Enzymatische Inaktivierung von Isonicotinsaurehydrazid im menschlichen und tierischen Organismus. Arch Exp Pathol Pharmakol 220: 321–333Google Scholar
  14. Botsch S, Gautier JC, Beaune P, Eichelbaum M, Kroemer HK (1993) Identification and characterization of the cytochrome P450 enzymes involved in N-dealkylation of propafenone: molecular base for interaction potential and variable disposition of active metabolites. Mol Pharmacol 43: 120–126PubMedGoogle Scholar
  15. Brian WR, Srivastava PK, Umbenhauer DR, Lloyd RS, Guengerich FP (1989) Expression of a human liver cytochrome P-450 protein with tolbutamide hydroxylase activity in Saccharomyces cerevisiae. Biochemistry 28: 4993–4999PubMedGoogle Scholar
  16. Broly F, Gaedigk A, Heim M, Eichelbaum M, Mörike K, Meyer UA (1991) Debrisoquine/sparteine hydroxylation genotype and phenotype: analysis of common mutations and alleles of CYP2D6 in a European population. DNA Cell Biol 10: 545 - 558PubMedGoogle Scholar
  17. Brosen K, Gram LF (1988) First-pass metabolism of imipramine and desipramine: impact of the sparteine oxidation phenotype. Clin Pharmacol Ther 43: 400–406PubMedGoogle Scholar
  18. Brosen K, Gram LF, Klysner R, Bech P (1986) Steady-state levels of imipramine and its metabolites: significance of dose-dependent kinetics. Eur J Clin Pharmacol 30: 43–49PubMedGoogle Scholar
  19. Brosen K, Gram LF, Haghfelt T, Bertilsson L (1987) Extensive metabolizers of debrisoquine become poor metabolizers during quinidine treatment: Pharmacol Toxicol 60: 312–314PubMedGoogle Scholar
  20. Burchell B, Coughtrie MWH (1992) UDP-glucuronosyltransferases. In: Kalow W (ed) Pharmacogenetics of drug metabolism. Pergamon, New York, pp 95–165Google Scholar
  21. Chen ZR, Somogyi AA, Bochner F (1988) Polymorphic O-demethylation of codeine. Lancet 2: 914–915PubMedGoogle Scholar
  22. Clark DWJ, Morgan AKW, Waal-Manning H (1984) Adverse effects from metoprolol are not generally associated with oxidation status. Br J Clin Pharmacol 18: 965–966PubMedGoogle Scholar
  23. Cooper RG, Evans DAP, Whibley EJ (1984) Polymorphic hydroxylation of perhexiline maleate in man. J Med Genet 21: 27–33PubMedGoogle Scholar
  24. Dahl-Puustinen ML, Liden A, Aim C, Nordin C, Bertilsson L (1989) Disposition of perphenazine is related to the polymorphic debrisoquine hydroxylation in human beings. Clin Pharmacol Ther 46: 78–81PubMedGoogle Scholar
  25. Dayer P, Leemann T, Kiipfer A, Kronbach T, Meyer UA (1986) Stereo- and regioselectivity of hepatic oxidation in man—effect of the debrisoquine/sparteine phenotype on bufuralol hydroxylation. Eur J Clin Pharmacol 31: 313–318PubMedGoogle Scholar
  26. Dayer P, Desmeules J, Leemann T, Striberni R (1988) Bioactivation of the narcotic drug codeine in human liver is mediated by the polymorphic monooxygenase catalyzing debrisoquine 4-hydroxylation (cytochrome P-450 dbl/bufl). Biochem Biophys Res Commun 152: 4161–4165Google Scholar
  27. Deguchi T, Mashimo M, Suzuki T (1990) Correlation between acetylator phenotype and genotypes of polymorphic arylamine N-acetyltransferase in human liver. J Biol Chem 265: 12757–12760PubMedGoogle Scholar
  28. Drayer DE, Reidenberg DM (1977) Clinical consequences of polymorphic acetylation of basic drugs. Clin Pharmacol Ther 22: 251–258PubMedGoogle Scholar
  29. Ebner T, Eichelbaum M (1993) The metabolism of aprindine in relation to the sparteine/debrisoquine polymorphism. Br J Clin Pharmacol 35: 426–430PubMedGoogle Scholar
  30. Eichelbaum M (1975) Ein neuentdeckter Defekt im Arzneimittelstoffwechsel des Menschen: Die fehlende N-Oxidation des Spartein. Habilitationsschrift, Friedrich-Wilhelms-University, BonnGoogle Scholar
  31. Eichelbaum M, Gross AS (1992) The genetic polymorphism of debrisoquine sparteine metabolism—clinical aspects. In: Kalow W (ed) Pharmacogenetics of drug metabolism. Pergamon, New York, pp 625–643Google Scholar
  32. Eichelbaum M, Spannbrucker N, Steincke B, Dengler HJ (1979) Defective Noxidation of sparteine in man: a new pharmacogenetic defect. Eur J Clin Pharmacol 16: 183–187PubMedGoogle Scholar
  33. Eichelbaum M, Baur MP, Dengler HJ, Osikowska-Evers BO, Tieves G, Zekorn C, Rittner C (1987) Chromosomal assignment of human cytochrome P450 (debrisoquine/sparteine type) to chromosome 22. Br J Clin Pharmacol 23: 455–458PubMedGoogle Scholar
  34. Evans DAP (1992) N-acetyltransferase. In: Kalow W (ed) Pharmacogenetics of drug metabolism. Pergamon, New York, pp 95–165Google Scholar
  35. Evans DAP, Manley KA, McKusick VA (1960) Genetic control of isoniazid metabolism in man. Br Med J 2: 485–461PubMedGoogle Scholar
  36. Evans DAP, Mahgoub A, Sloan TP, Idle JR, Smith RL (1980) A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population. J Med Genet 17: 102–105PubMedGoogle Scholar
  37. Evans DAP, Eze LZ, Whibley EJ (1983) The association of the slow acetylator phenotype with bladder cancer. J Med Genet 20: 321–329PubMedGoogle Scholar
  38. Feher MD, Lucas RA, Farid NA, Idle JR, Bergstrom RF, Lemberger L, Sever PS (1988) Single dose pharmacokinetics of tomoxetine in poor and extensive metabolisers of debrisoquine. Br J Clin Pharmacol 26: 231 PGoogle Scholar
  39. Fischer V (1992) Polymorphic drug metabolism and its consequences for drug development (Abstr). 13th European Workshop on Drug Metabolism, BergamoGoogle Scholar
  40. Fischer V, Vogels B, Maurer G, Tynes RE (1992) The antipsychotic clozapine is metabolized by the polymorphic human microsomal and recombinant cytochrome P450 2D6. J Pharmacol Exp Ther 260: 1355–1360PubMedGoogle Scholar
  41. Funck-Brentano C, Turgeon J, Woosley RL, Roden DM (1989) Effects of low dose quinidine on encainide pharmacokinetics and pharmacodynamics. Influence of genetic polymorphism. J Pharmacol Ther 249: 134–142Google Scholar
  42. Gaedigk A, Blum M, Gaedigk R, Eichelbaum M, Meyer UA (1991) Deletion of the entire cytochrome P450 CYP2D6 gene as a cause of impaired drug metabolism in poor metabolizers of the debrisoquine/sparteine polymorphism. Am J Hum Genet 48: 943–950PubMedGoogle Scholar
  43. Garrod AE (1902) The incidence of alcaptonuria: a study in chemical individuality. Lancet 2: 1616–1620Google Scholar
  44. Garrod AE (1931) The inborn factors of disease. Oxford University Press, LondonGoogle Scholar
  45. Ged C, Umbenhauer DR, Bellew TM, Bork RW, Srivastava PK, Shinriki N, Lloyd RS, Guengerich FP (1988) Characterization of cDNAs, mRNAs and proteins related to human liver microsomal cytochrome P450 S-mephenytoin 4-hydroxylase. Biochemistry 27: 6929–6940PubMedGoogle Scholar
  46. Gleiter CH, Aichele G, Nilsson E, Hengen N, Antonin KH, Bieck PR (1985) Discovery of altered pharmacokinetics of CGP 15210G in poor hydroxylators of debrisoquine during early drug development. Br J Clin Pharmacol 20: 81–84PubMedGoogle Scholar
  47. Goedde HW, Agarwal DP (1992) Pharmacogenetics of aldehyde dehydrogenase. In: Kalow W (ed) Pharmacogenetics of drug metabolism. Pergamon, New York, pp 281–314Google Scholar
  48. Gonzalez FJ (1992) Pharmacogenetics redefined. Trends Pharmacol Sci 13: 348Google Scholar
  49. Gonzalez FJ, Skoda RC, Kimura S, Umeno M, Zanger UM, Nebert DW, Gelboin HV, Hardwick JP, Meyer UA (1988) Characterization of the common genetic defect in humans deficient in debrisoquine metabolism. Nature 331: 442–446PubMedGoogle Scholar
  50. Gram LF (1975) Effects of perphenazine on imipramine metabolism in man. Psychopharmacol Commun 1: 165–175PubMedGoogle Scholar
  51. Gram LF, Overo KF (1972) Drug interaction: inhibitory effect of neuroleptics on metabolism of tricyclic antidepressants in man. Br Med J 163: 463 - 465Google Scholar
  52. Gram LF, Debruyne D, Caillard V, Boulenger JP, Lacotte J, Moulin M, Zarifian E (1989) Substantial rise in sparteine metabolic ratio during haloperidol treatment. Br J Clin Pharmacol 27: 272–275PubMedGoogle Scholar
  53. Grant DM, Blum M, Demierre A, Meyer UA (1989) Nucleotide sequence for an intronless gene for a human arylamine Af-acetyltransferase related to polymorphic drug acetylation. Nucleic Acids Res 17: 3978PubMedGoogle Scholar
  54. Grant DM, Mörike K, Eichelbaum M, Meyer UA (1990) Acetylation pharmacogenetics. The slow acetylator phenotype is caused by decreased or absent arylamine N-acetyltransferase in human liver. J Clin Invest 85: 968–972PubMedGoogle Scholar
  55. Grant DM, Tang BK, Kalow W (1984) Polymorphic N-acetylation of a caffeine metabolite. Clin Pharmacol Ther 33: 355–359Google Scholar
  56. Guengerich FP, Distlerath LM, Reilly PEB, Wolff T, Shimada T, Umbenhauer DR, Martin MV (1986) Human-liver cytochromes P-450 involved in polymorphisms of drug oxidation. Xenobiotica 16: 367–378PubMedGoogle Scholar
  57. Hall SD, Guengerich FP, Branch RA, Wilkinson GR (1987) Characterization and inhibition of mephenytoin 4-hydroxylase activity in human liver microsomes. J Pharmacol Exp Ther 240: 216–222PubMedGoogle Scholar
  58. Heim M, Meyer UA (1990) Genotyping of poor metabolizers of debrisoquine by allele specific PCR-amplification. Lancet 336: 529–532PubMedGoogle Scholar
  59. Heim M, Meyer UA (1992) Evolution of a highly polymorphic human cytochrome P450 gene cluster: CYP2D6. Genomics 14: 49–58PubMedGoogle Scholar
  60. Hickman D, Risch A, Camilleri JP, Sim E (1992) Genotyping human arylamine N-acetyltransferase: identification of new allotypic variants. Pharmacogenetics 2: 217–226PubMedGoogle Scholar
  61. Horai Y, Fujita K, Ishizaki T (1989) Genetically determined N-acetylation and oxidation capacities in Japanese patients with non occupational urinary bladder cancer. Eur J Clin Pharmacol 37: 581–587PubMedGoogle Scholar
  62. Hori R, Okumura K, Inui KI, Yasuhara M, Yamada K, Sakurai T, Kawai C (1984) Quinidine-induced rise in ajmaline plasma concentration. J Pharm Pharmacol 36: 202–204PubMedGoogle Scholar
  63. Hughes HB, Schmidt LH, Biehl JP (1955) The metabolism of isoniazide, its implications in therapeutic use. 14th Conference on Chemotherapy in Tuberculosis, Washington DC, US Veterans Adm Army Navy, pp 217–222Google Scholar
  64. Inaba T, Jurima M, Kalow W (1986) Family studies of mephenytoin hydroxylation deficiency. Am J Hum Genet 38: 768–772PubMedGoogle Scholar
  65. Iselius L, Evans DAP (1983) Formal genetics of isoniazid metabolism in man. Clin Pharmacol Ther Clin Pharmacokinet 8: 541–544Google Scholar
  66. Islam SA, Wolf CR, Lennard MS, Sternberg MJE (1991) A three-dimensional molecular template for substrates of human cytochrome P450 involved in debrisoquine 4-hydroxylation. Carcinogenesis 12: 2211–2219PubMedGoogle Scholar
  67. Jacqz E, Hall SD, Branch RA, Wilkinson GR (1986) Polymorphic metabolism of mephenytoin in man: pharmacokinetic interaction with a coregulated substrate, mephobarbital. Clin Pharmacol Ther 39: 646–653PubMedGoogle Scholar
  68. Jenne JW (1965) Partial purification and properties of the isoniazide transacetylase in human liver: its relationship to the acetylation of para-amino salicylic acid. J Clin Invest 44: 1992–2002Google Scholar
  69. Jurima M, Inaba T, Kalow W (1985) Mephenytoin metabolism in vitro by human liver. Drug Metab Dispos 13: 151–155PubMedGoogle Scholar
  70. Kagimoto M, Heim M, Kagimoto K, Zeugin T, Meyer UA (1990) Multiple mutations of the human cytochrome P450IID6 gene (CYP2D6) in poor metabolizers of debrisoquine. J Biol Chem 265: 17209–17214PubMedGoogle Scholar
  71. Kalow W (1956) Familial incidence of low pseudocholinesterase level. Lancet 2: 576–577Google Scholar
  72. Kalow W, Genest K (1957) A method for the detection of atypical forms of the human serum cholinesterase. Determination of dibucaine numbers. Can J Biochem Physiol 35: 339–346PubMedGoogle Scholar
  73. Kalow W, Staron N (1957) On distribution and inheritance of atypical forms of human serum cholinesterase as indicated by dibucaine numbers. Can J Biochem Physiol 35: 1305–1320PubMedGoogle Scholar
  74. Kitchen I, Tremblay J, Andre J, Dring LG, Idle JR, Smith RL, Williams RT (1979) Inter-individual and inter-species variation in the metabolism of the hallucinogen 4-methoxyamphetamine. Xenobiotica 9: 397–404PubMedGoogle Scholar
  75. Knodell RG, Dubey RK, Wilkinson GR, Guengerich FP (1988) Oxidative metabolism of hexobarbital in human liver: relationship to polymorphic S-mephenytoin 4-hydroxylation. J Pharmacol Exp Ther 245: 845–849PubMedGoogle Scholar
  76. Kroemer HK, Mikus G, Kronbach T, Meyer UA, Eichelbaum M (1989) In vitro characterization of the human cytochrome P-450 involved in polymorphic oxidation of propafenone. Clin Pharmacol Ther 45: 28–33PubMedGoogle Scholar
  77. Küpfer A, Branch RA (1985) Stereoselective mephobarbital hydroxylation cosegregates with mephenytoin hydroxylation. Clin Pharmacol Ther 38: 414–418PubMedGoogle Scholar
  78. Küpfer A, Preisig R (1984) Pharmacogenetics of mephenytoin: a new drug hydroxylation polymorphism in man. Eur J Clin Pharmacol 26: 753–759PubMedGoogle Scholar
  79. Küpfer A, Schmid B, Preisig R, Pfaff G (1984) Dextromethorphan as a safe probe for debrisoquine hydroxylation polymorphism. Lancet 1: 517–518Google Scholar
  80. Lee JT, Kroemer HK, Silberstein DJ, Funck-Brentano C, Lineberry MD, Wood AJJ, Roden DM, Woosley RL (1990) The role of genetically determined polymorphic drug metabolism in the beta-blockade produced by propafenone. N Engl J Med 322: 1764–1768PubMedGoogle Scholar
  81. Leemann T, Dayer P, Meyer UA (1986) Single-dose quinidine treatment inhibits metoprolol oxidation in extensive metabolizers. Eur J Clin Pharmacol 29: 739–741PubMedGoogle Scholar
  82. Lennard MS (1992) The polymorphic oxidation of β-adrenoceptor antagonists. In: Kalow W (ed) Pharmacogenetics of drug metabolism. Pergamon, New York, pp 701–720Google Scholar
  83. Lewis RV, Lennard MS, Jackson PR, Tucker GT, Ramsay LE, Woods HF (1985) Timolol and atenolol: relationships between oxidation phenotype, pharmacokinetics and pharmacodynamics. Br J Clin Pharmacol 19: 329–333PubMedGoogle Scholar
  84. Llerena A, Dahl MJ, Ekqvist B, Bertilsson L (1992) Haloperidol disposition is dependent on the debrisoquine hydroxylation phenotype: increased plasma levels of the reduced metabolite in poor metabolizers. Ther Drug Monit 14: 261–264PubMedGoogle Scholar
  85. Lockridge O (1992) Genetic variants of human serum butyrylcholinesterase influence the metabolism of the muscle relaxant succinylcholine. In: Kalow W (ed) Pharmacogenetics of drug metabolism. Pergamon, New York, pp 15–50Google Scholar
  86. Mahgoub A, Idle JR, Dring LG, Lancaster R, Smith RL (1977) Polymorphic hydroxylation of debrisoquine in man. Lancet 2: 584–586PubMedGoogle Scholar
  87. McGourty JC, Silas JH, Fleming JJ, McBurney A, Ward JW (1985) Pharmacokinetics and beta-blocking effects of timolol in poor and extensive metabolisers of debrisoquin. Clin Pharmacol Ther 38: 409–413PubMedGoogle Scholar
  88. McGuire MC, Nogueira CP, Bartels CF, Lightstone H, Hajra A, van der Spek AFL, Lockridge O, La Du BN (1989) Identification of the structural mutation responsible for the dibucaine resistant (atypical) variant form of human serum cholinesterase. Proc Natl Acad Sci USA 86: 953–957PubMedGoogle Scholar
  89. Meier UT, Meyer UA (1987) Genetic polymorphism of cytochrome P450 (5)-mephenytoin 4-hydroxylase. Studies with human autoantibodies suggest a functionally altered P450 enzyme as cause of genetic deficiency. Biochemistry 26: 8466–8474PubMedGoogle Scholar
  90. Meier UT, Dayer P, Male PJ, Kronbach T, Meyer UA (1985) Mephenytoin hydroxylation polymorphism: characterization of the enzymatic deficiency in liver microsomes of poor metabolizers phenotyped in vivo. Clin Pharmacol Ther 38: 488–494PubMedGoogle Scholar
  91. Mellström B, Bertilsson L, Lou Y-C, Sawe J, Sjoqvist F (1983) Amitryptiline metabolism: relationship to polymorphic debrisoquine hydroxylation. Clin Pharmacol Ther 34: 516–520PubMedGoogle Scholar
  92. Meyer UA, Gut J, Kronbach T, Skoda C, Meier UT, Catin T, Dayer P (1986) The molecular mechanisms of two common polymorphisms of drug oxidation—evidence for functional changes in cytochrome P-450 isozymes catalysing bufuralol and mephenytoin oxidation. Xenobiotica 16: 449–464PubMedGoogle Scholar
  93. Meyer UA, Skoda RC, Zanger UM, Heim M, Broly F (1992) The genetic polymorphism of debrisoquine/sparteine polymorphism - molecular mechanisms. In: Kalow W (ed) Pharmacogenetics of drug metabolism. Pergamon, New York, pp 609–624Google Scholar
  94. Mitchell RS, Bell JC (1957) Clinical implications of isoniazide, PAS and streptomycin blood levels in pulmonary tuberculosis. Trans Am Clin Chem Assoc 69: 98–105Google Scholar
  95. Mörike K, Hardtmann E, Heimburg P (1990) Interindividual variation of N-propylajmaline dose requirement in patients with ventricular arrhythmia in relation to metabolic capacity of sparteine ( Abstr ). Naunyn Schmiedebergs Arch Pharmacol 341: 110Google Scholar
  96. Mortimer Ö, Lindstrom B, Laurell H, Bergman U, Rane A (1989) Dextromethorphan: polymorphic serum pattern of the O-demethylated and didemethylated metabolites in man. Br J Clin Pharmacol 27: 223–227PubMedGoogle Scholar
  97. Motulsky AG (1957) Drug reactions, enzymes and biochemical genetics. JAMA 165: 835–837Google Scholar
  98. Nebert DW, Nelson DR, Feyereisen R, Fuji-Kuriyama Y, Coon MJ, Estabrook RW, Gonzolez FJ, Guengerich FP, Gunsalus IC, Johnson EF, Loper JC, Sato R, Waterman MR, Waxman DJ (1991) The P450 superfamily: update on new sequences, gene mapping and recommended nomenclature. DNA Cell Biol 10: 1–14PubMedGoogle Scholar
  99. Nelson JC, Jatlow PI (1980) Neuroleptic effect on desipramine steady-state plasma concentrations. Am J Psychiatry 137: 1232–1234PubMedGoogle Scholar
  100. Newton BW, Benson RC, McCarriston CC (1966) Sparteine sulphate: a potent capricious oxytocic. Am J Obstet Cynecol 94: 234–241Google Scholar
  101. Nordin C, Siwers B, Benitez J, Bertilsson L (1985) Plasma concentrations of nortriptyline and its 10-hydroxy metabolite in depressed patients—relationship to the debrisoquine hydroxylation ratio. Br J Clin Pharmacol 19: 832–835PubMedGoogle Scholar
  102. Oates NS, Shah RR, Idle JR, Smith RL (1982) Genetic polymorphism of phenformin 4-hydroxylation. Clin Pharmacol Ther 32: 81–89PubMedGoogle Scholar
  103. Okino ST, Quattrochi LC, Pendurthi UR, McBride OW, Tukey RH (1987) Characterization of multiple human cytochrome P4501 cDNAs: the chromosomal localization of the gene and evidence for alternate RNA splicing. J Biol Chem 262: 16072–16079PubMedGoogle Scholar
  104. Pierce DM, Smith SE, Franklin RA (1987) The pharmacokinetics of indoramin and 6-hydroxyindoramin in poor and extensive hydroxylators of debrisoquine. Eur J Clin Pharmacol 33: 59–65PubMedGoogle Scholar
  105. Raghuram TC, Koshakji RP, Wilkinson GR, Wood AJJ (1984) Polymorphic ability to metabolize propranolol alters 4-hydroxypropranolol levels but not beta blockade. Clin Pharmacol Ther 36: 51–56PubMedGoogle Scholar
  106. Rane A, Modiri AR, Gerdin E (1992) Ethylmorphine O-deethylation cosegregates with the debrisoquin genetic metabolic polymorphism. Clin Pharmacol Ther 52: 257–264PubMedGoogle Scholar
  107. Rao KVN, Mitchison DA, Nair NGK, Prema K, Tripathy SP (1970) Sulfadimidine acetylation test for classification of patients as slow or rapid inactivators of isoniazide. Br Med J 3: 495–497PubMedGoogle Scholar
  108. Regardh CG, Johnson G (1984) Interindividual variations in metoprolol metabolism—some clinical and other observations. Br J Clin Pharmacol 17: 495–496PubMedGoogle Scholar
  109. Robitzek EH, Selikoff IJ, Ornstein GG (1952) Chemotherapy of human tuberculosis with hydrazine derivatives of isonicotinic acid. Q Bull Sea View Hosp NY 13: 27–51Google Scholar
  110. Rost KL, Brosicke H, Brockmoller J, Scheffler M, Helge H, Roots I (1992) Increase of cytochrome P4501A2 activity by omeprazole: evidence by the 13C-[Af-3-methyl]-caffeine breath test in poor and extensive metabolizers of 5-mephenytoin. Clin Pharmacol Ther 52: 170–180PubMedGoogle Scholar
  111. Roy SS, Hawes EM, McKay G, Korchinski ED, Midha KK (1985) Metabolism of methoxyphenamine in extensive and poor metabolisers of debrisoquin. Clin Pharmacol Ther 38: 128–133PubMedGoogle Scholar
  112. Schmid B, Bircher J, Preisig R, Kiipfer A (1985) Polymorphic dextromethorphan metabolism: co-segregation of oxidative O-demethylation with debrisoquin hydroxylation. Clin Pharmacol Ther 38: 618–624PubMedGoogle Scholar
  113. Shah RR, Oates NS, Idle JR, Smith RL, Lockhart JDF (1982) Impaired oxidation of debrisoquine in patients with perhexiline neuropathy. Br Med J 284: 295–299Google Scholar
  114. Shah RR, Oates NS, Idle JR, Smith RL, Lockhart DF (1983) Prediction of subclinical perhexiline neuropathy in a patient with inborn error of debrisoquine hydroxylation. Am Heart J 105: 159–161PubMedGoogle Scholar
  115. Shimada T, Misono KS, Guengerich FP (1986) Human liver microsomal cytochrome P450 mephenytoin hydroxylase, a prototype of genetic polymorphism in oxidative drug metabolism: purification and characterization of two similar forms involved in the reaction. J Biol Chem 261: 909–921PubMedGoogle Scholar
  116. Siddoway LA, Thompson KA, McAllister B, Wang T, Wilkinson GR, Roden DM, Woosley RL (1987) Polymorphism of propafenone metabolism and disposition in man: clinical and pharmacokinetic consequences. Circulation 75: 785–791PubMedGoogle Scholar
  117. Sindrup SH, Brosen K, Bjerring P, Arendt-Nielsen L, Larsen U, Angelo HR, Gram LF (1990) Codeine increases pain thresholds to copper vapor laser stimuli in extensive but not in poor metabolizers of sparteine. Clin Pharmacol Ther 48: 686–693PubMedGoogle Scholar
  118. Skjelbo E, Brosen K, Hallas J, Gram LF (1991) The mephenytoin oxidation polymorphism is partially responsible for the N-demethylation of imipramine. Clin Pharmacol Ther 49: 18–23PubMedGoogle Scholar
  119. Skoda R, Gonzalez FJ, Demierre A, Meyer UA (1988) Two mutant alleles of the human cytochrome P450 dbl gene (P450 IID1) associated with genetically deficient metabolism of debrisoquine and other drugs. Proc Natl Acad Sci USA 85: 5240–5243PubMedGoogle Scholar
  120. Sloan TP, Mahgoub A, Lancaster R, Idle JR, Smith RL (1978) Polymorphism of carbon oxidation of drugs and clinical implications. Br Med J 2: 655–657PubMedGoogle Scholar
  121. Srivastava PK, Yun CH, Beaune P, Ged C, Guengerich FP (1991) Separation of human liver microsomal tolbutamide hydroxylase and S-mephenytoin 4′-hydroxylase cytochrome P450 enzymes. Mol Pharmacol 40: 69–79PubMedGoogle Scholar
  122. Vatsis KP, Martell KJ, Weber WW (1991) Diverse point mutations in the human gene for polymorphic N-acetyltransferase. Proc Natl Acad Sci USA 88: 6333–6337PubMedGoogle Scholar
  123. Vogel F (1959) Moderne Probleme der Humangenetik. Ergeb Inn Med Kinderheilkol 12: 52–125Google Scholar
  124. Vogel F, Motulsky AG (1979) Human genetics. Springer, Berlin Heidelberg New YorkGoogle Scholar
  125. Von Bahr C, Movin G, Nordin C, Liden A, Hammarlund-Udenaes M, Hedberg A, Ring H, Sjoqvist F (1991) Plasma levels of thioridazine and metabolites are influenced by the debrisoquine hydroxylation phenotype. Clin Pharmacol Ther 49: 234–240Google Scholar
  126. Wagner F, Kalusche D, Trenk D, Jahnchen E, Roskamm H (1987) Drug interaction between propafenone and metoprolol. Br J Clin Pharmacol 24: 213–220PubMedGoogle Scholar
  127. Wang T, Roden DM, Wolfenden HT, Woosley RL, Wood AJJ, Wilkinson GR (1984) Influence of genetic polymorphism on the metabolism and disposition of encainide in man. J Pharmacol Exp Ther 228: 605–611PubMedGoogle Scholar
  128. Ward SA, Walle T, Walle K, Wilkinson GR, Branch RA (1989) Propranolol’s metabolism is determined by both mephenytoin and debrisoquine hydroxylase activities. Clin Pharmacol Ther 45: 72–79PubMedGoogle Scholar
  129. Ward SA, Helsby NA, Skjelbo E, Brosen K, Gram LF, Breckenridge AM (1991) The activation of the biguanide antimalarial proguanil cosegregates with the mephenytoin oxidation polymorphism—a panel study. Br J Clin Pharmacol 31: 689–692PubMedGoogle Scholar
  130. Wedlund PJ, Aslani WS, McAllister CB, Wilkinson GR, Branch RA (1984) Mephenytoin hydroxylation deficiency in Caucasians: frequency of a new oxidative drug metabolism polymorphism. Clin Pharmacol Ther 36: 773–780PubMedGoogle Scholar
  131. Weinshilbaum R (1992) Methyltransferase pharmacogenetics. In: Kalow W (ed) Pharmacogenetics of drug metabolism. Pergamon, New York, pp 179–194Google Scholar
  132. Wilkinson GR, Guengerich FP, Branch RA (1992) Genetic polymorphism of S-mephenytoin hydroxylation. In: Kalow W (ed) Pharmacogenetics of drug metabolism. Pergamon, New York, pp 657–680Google Scholar
  133. Woosley RL, Drayer DE, Reidenberg MM, Nies AS, Carr K, Oates JA (1978) Effect of acetylator phenotype on the rate at which procainamide induces antinuclear antibodies and the lupus syndrome. N Engl J Med 298: 1157–1159PubMedGoogle Scholar
  134. Zekorn C, Achtert G, Hausleiter HJ, Moon CH, Eichelbaum M (1985) Pharmacokinetics of TV-propylajmaline in relation to polymorphic sparteine oxidation. Klin Wochenschr 63: 1180–1186PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1994

Authors and Affiliations

  • H. K. Kroemer
  • G. Mikus
  • M. Eichelbaum

There are no affiliations available

Personalised recommendations